Rice University announced a new climate tech initiative backed by Woodside Energy. Photo by Natalie Harms/InnovationMap

Rice University has announced its latest initiative to advance clean energy technology into commercialization with a new partnership with a global energy company.

Woodside Energy, headquartered in Australia with its global operations in Houston following its 2022 acquisition of BHP Group, has committed $12.5 million over the next five years to create the Woodside Rice Decarbonization Accelerator.

"The goal of the accelerator is to fast track the commercialization of innovative decarbonization technologies created in Rice labs," Rice University President Reginald DesRoches says to a crowd at the Ion at the initiative's announcement. "These technologies have the potential to make better batteries, transitistors, and other critical materials for energy technologies. In addition, the accelerator will work on manufacturing these high-value products from captured and converted carbon dioxide and methane."

"The Woodside Rice Decarbonization Accelerator will build on the work that Rice has been doing in advanced materials, energy, energy transition, and climate for many years. More than 20 percent of our faculty do some related work to energy and climate," he continues. "Harnessing their efforts alongside an esteemed partner like Woodside Energy is an exciting step that will undoubtedly have an impact far and wide."

Woodside, which has over 800 employees based in Houston, has been a partner at the Ion since last spring. Daniel Kalms, Woodside Energy's CTO and executive vice president, explains that the new initiative falls in line with the three goals of Woodside's climate strategy, which includes keeping up with global energy demand, creating value, and conducting its business sustainably. The company has committed a total of $5 billion to new energy by 2030, Kalms says.

"We know that the world needs energy that is more affordable, sustainable, and secure to support the energy transition — and we want to provide that energy. Energy that is affordable, sustainable, and secure requires innovation and the application of new technology. That's what this is about," he says.

"Of course collaboration will be the key," Kalms continues. "By working with researchers, entrepreneurs, leading experts and parallel industries, we can combine our capability to solve collective challenges and create shared opportunities. That's why we are excited to be partnering with Rice."

The accelerator will be run by Paul Cherukuri, vice president of innovation at Rice University, and Aditya Mohite, associate professor of Chemical and Biomolecular Engineering and Materials Science and Nanoengineering. Additional Rice professors will be involved as well, Cherukuri says.

"Success for us will not be papers, it will be products," Cherukuri says of what Woodside wants from the partnership. "We picked faculty at Rice in particular who were interested in taking on this charge, and they were all faculty who created companies."

Last fall, Rice announced a grant and venture initiative to accelerate innovation from Rice in the biotech space.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.